

Session Title: #237: Cancer and Thrombosis: Risk, Prevention, and Treatment

Session Type: Extended Education Session

Date: Friday, June 4

Location: E354a

Time: 1:00 PM - 3:15 PM

- Review currently available guidelines for the prevention of cancer-associated thrombosis

Gary H. Lyman, MD, MPH

- Review the incidence and prevalence of cancer-associated thrombosis

Alok A. Khorana, MD

- Risk of VTE in patients receiving newer cancer therapies

Howard A. Liebman, MD

- Prevention of VTE in hospitalized medical patients

Charles W. Francis, MD

- Prevention of VTE in surgical cancer patients

Ajay Kumar Kakkar, MD

- Prevention of VTE in ambulatory cancer patients receiving chemotherapy

Mark Norman Levine, MD

- Current and future clinical trials of VTE prophylaxis in cancer patients

Anna Falanga, MD

- Diagnosis and initial treatment of VTE in cancer patients

Craig M. Kessler, MD

- Special populations and extended anticoagulation of cancer patients for the prevention of recurrent VTE prevention of recurrent VTE

Agnes Y. Y. Lee, MD, MSc, FRCP(C)

Session Title: #275: Childhood Cancer Survivorship: Lessons Learned and Future Steps

Session Type: Extended Education Session

Date: Friday, June 4

Location: S504

Time: 1:00 PM - 3:15 PM

- Childhood Cancer Survivorship: Lessons Learned and Future Steps

Kevin C. Oeffinger, MD

- Current guidelines for follow up of the survivors of pediatric cancers. Current new areas of research including issues related to genetic susceptibility to toxicities

Smita Bhatia, MD, MPH

- Long-term psycho-social effects following the treatment of pediatric cancers.

Christopher Recklitis, MPH, PhD

- Discussion of the Childhood Cancer Survivor Study (CCSS)

Leslie L. Robison, PhD

- Discussion of the Childhood Cancer Survivor Study (CCSS)

Gregory T. Armstrong, MD, MSCE

Session Title: #43: Electronic Health Records in Oncology: A requirement for 2014

Session Type: Education Session

Date: Friday, June 4

Location: E353

Time: 4:30 PM - 5:45 PM

- So you want me to adopt EHR by 2014?

Jonathan B. Perlin, MD, PhD, MSHA, FACP, FACMI

- Interoperability: Getting the relevant information to the right place in real time

Peter Paul Yu

- Getting more out of your EHR

Lawrence N. Shulman, MD

Session Title: #183: Health Services Research

Session Type: Poster Discussion Session

- Health Services Research

Benjamin D. Smith, MD

- Health Services Research

Elissa Ozanne, PhD

1 #6009-Burden of illness estimates of metastatic breast cancer (MBC) in the United States.

Sonja Sorensen

2 #6010-Adjuvant endocrine monotherapy with tamoxifen or aromatase inhibitors for postmenopausal women with breast cancer: What is the economic impact of CYP 2D6 testing?

Tallal Younis

3 #6011-Comparative effectiveness of screening, surgery, and chemoprevention among BRCA1/2 mutation carriers.

Victor Grann, MD, MPH

4 #6012-Therapeutic options for low-risk prostate cancer: A cost-effectiveness analysis.

Julia H Hayes

5 #6013-Year one evaluation of regional pay for quality (P4Q) oncology program.

Jeffrey A. Scott

6 #6014-Conflicts of interest in economic analyses presented at the American Society of Clinical Oncology Annual Meeting.

Sekwon Jang

7 #6015-Does increasing insurance improve outcomes for U.S. cancer patients?

Jillian K Smith

- Discussion: Role of cost and comparative effectiveness research in guiding health policy

Elena B. Elkin, PhD

8 #6016-Surgeon influence on patient appraisal of ASCO breast cancer quality indicators.

Sarah T. Hawley, MD, PhD

9 #6017-The impact of audit and feedback on nodal harvest in colorectal cancer (CRC).

Geoffrey A. Porter

10 #6018-Quality of care in non-small cell lung cancer (NSCLC): Findings from the Florida initiative for quality cancer care (FIQCC).

Tawee Tanvetyanon

11 #6019-Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma: Evaluating community guideline adherence.

Nader N Massarweh, MD

12 #6020-Scientific evidence underlying National Comprehensive Cancer Network Clinical Practice Guidelines.

Thejaswi K.Poonacha

- Discussion: Oncology guidelines: adherence and appraisal

Jennifer Malin

13 #6021-End of life care for elderly patients with advanced lung cancer in the United States and Ontario.

K. Robin Yabroff

14 #6022-Impact of care at NCI-designated Comprehensive Cancer Centers (NCICCCs) on racial differences in prostate cancer-specific survival.

Can-Lan Sun

15 #6023-Trends in prostatectomy: Centralization, robotics, and access to care.

Karyn Beth Stitzenberg

16 #6024-PSA surveillance in men with localized prostate cancer.

Debra Nana Yeboa

17 #6025-Restoration of medical oncology services at Charity Hospital in New Orleans after Hurricane Katrina: A 2-year experience of the Louisiana State University Health Sciences Center (LSUHSC).

Brian C. Boulmay, MD

18 #6026-Appropriateness of cardiovascular (CV) care in cancer survivors (CS).

Winson Y. Cheung

19 #6027-Estimation of the U.S. rate of neutropenic complications for cancer hospital discharges.

Mike Dickson

- Discussion: Patterns of cancer care

Stephen B. Edge, MD

20 #6028-Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs).

Bostjan Seruga

21 #6029-A compendium of unpublished phase III clinical trials in oncology: Characteristics and impact on clinical practice.

Vincent Channing Tam, MD, FRCPC

22 #6030-The assessment of cost and other barriers to patient clinical trial participation in the community setting.

Douglas Weckstein

23 #6031-Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.

Benoit You

24 #6032-Influence of nonclinical patient factors on decisions to recommend breast cancer adjuvant chemotherapy.

Tunghi May Pini, MD, MPH

25 #6033-Factors associated with decision making for use of adjuvant chemotherapy (AT) in referred patients (pts) with resected high-risk colon cancer (CC).

Doran Ksienski

- Discussion: Clinical trials and decision making

Benjamin Djulbegovic, MD, PhD

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #250: Health Services Research

Session Type: Poster Discussion Session

Date: Saturday, June 5

Location: S504

Time: 12:00 PM - 1:00 PM

- Health Services Research

Benjamin D. Smith, MD

- Health Services Research

Elissa Ozanne, PhD

1 #6009-Burden of illness estimates of metastatic breast cancer (MBC) in the United States.

Sonja Sorensen

2 #6010-Adjuvant endocrine monotherapy with tamoxifen or aromatase inhibitors for postmenopausal women with breast cancer: What is the economic impact of CYP 2D6 testing?

Tallal Younis

3 #6011-Comparative effectiveness of screening, surgery, and chemoprevention among BRCA1/2 mutation carriers.

Victor Grann, MD, MPH

4 #6012-Therapeutic options for low-risk prostate cancer: A cost-effectiveness analysis.

Julia H Hayes

5 #6013-Year one evaluation of regional pay for quality (P4Q) oncology program.

Jeffrey A. Scott

6 #6014-Conflicts of interest in economic analyses presented at the American Society of Clinical Oncology Annual Meeting.

Sekwon Jang

7 #6015-Does increasing insurance improve outcomes for U.S. cancer patients?

Jillian K Smith

- Discussion: Role of cost and comparative effectiveness research in guiding health policy

Elena B. Elkin, PhD

8 #6016-Surgeon influence on patient appraisal of ASCO breast cancer quality indicators.

Sarah T. Hawley, MD, PhD

9 #6017-The impact of audit and feedback on nodal harvest in colorectal cancer (CRC).

Geoffrey A. Porter

10 #6018-Quality of care in non-small cell lung cancer (NSCLC): Findings from the Florida initiative for quality cancer care (FIQCC).

Tawee Tanvetyanon

11 #6019-Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma: Evaluating community guideline adherence.

Nader N Massarweh, MD

12 #6020-Scientific evidence underlying National Comprehensive Cancer Network Clinical Practice Guidelines.

Thejaswi K.Poonacha

- Discussion: Oncology guidelines: adherence and appraisal

Jennifer Malin

13 #6021-End of life care for elderly patients with advanced lung cancer in the United States and Ontario.

K. Robin Yabroff

14 #6022-Impact of care at NCI-designated Comprehensive Cancer Centers (NCICCCs) on racial differences in prostate cancer-specific survival.

Can-Lan Sun

15 #6023-Trends in prostatectomy: Centralization, robotics, and access to care.

Karyn Beth Stitzenberg

16 #6024-PSA surveillance in men with localized prostate cancer.

Debra Nana Yeboa

17 #6025-Restoration of medical oncology services at Charity Hospital in New Orleans after Hurricane Katrina: A 2-year experience of the Louisiana State University Health Sciences Center (LSUHSC).

Brian C. Boulmay, MD

18 #6026-Appropriateness of cardiovascular (CV) care in cancer survivors (CS).

Winson Y. Cheung

19 #6027-Estimation of the U.S. rate of neutropenic complications for cancer hospital discharges.

Mike Dickson

- Discussion: Patterns of cancer care

Stephen B. Edge, MD

20 #6028-Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs).

Bostjan Seruga

21 #6029-A compendium of unpublished phase III clinical trials in oncology: Characteristics and impact on clinical practice.

Vincent Channing Tam, MD, FRCPC

22 #6030-The assessment of cost and other barriers to patient clinical trial participation in the community setting.

Douglas Weckstein

23 #6031-Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.

Benoit You

24 #6032-Influence of nonclinical patient factors on decisions to recommend breast cancer adjuvant chemotherapy.

Tunghi May Pini, MD, MPH

25 #6033-Factors associated with decision making for use of adjuvant chemotherapy (AT) in referred patients (pts) with resected high-risk colon cancer (CC).

Doran Ksienski

- Discussion: Clinical trials and decision making

Benjamin Djulbegovic, MD, PhD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture
Douglas W. Blayney, MD
- Plenary Session including Science of Oncology Award and Lecture
Daniel F. Hayes, MD
- Plenary Session including Science of Oncology Award and Lecture
Frank McCormick, PhD, FRS
- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger
- Discussion
Elizabeth A. Eisenhauer, MD
- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).
Elisabeth A. Quoix
- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).
Yung-Jue Bang
- Discussion
Martin J. Edelman, MD
- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD
- Discussion: Ipilimumab: The light at the end of the tunnel?
Vernon K Sondak, MD

Session Title: #131: Incidental Findings on Imaging in the Patient with Cancer: A Prudent Approach to Evaluation and Management

Session Type: Clinical Problems in Oncology Session

Date: Sunday, June 6

Location: E451a

Time: 4:45 PM - 6:00 PM

- The Incidental Renal Mass: Evaluation and Management in the Cancer Patient

Scott Michael Gilbert, MD, MS

- The Incidental Adrenal Mass: Evaluation and Management in the Cancer Patient

J. Stuart Wolf, Jr., MD

- The Incidental Pulmonary Nodule: Evaluation and Management in the Cancer Patient

David E. Ost, MD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

Session Title: #20: Cancer Survivors: A Challenge to Health Care Systems Worldwide

Session Type: Special Session

Date: Monday, June 7

Location: S100b

Time: 8:00 AM - 9:15 AM

- ASCO's Efforts to Promote Survivorship Care

Douglas W. Blayney, MD

- Follow-up and other health care needs of cancer survivors: how are different health care systems meeting the challenge?

Eva Grunfeld, MD, D.Phil.

- Life-threatening long-term effects after cancer: Who needs what follow-up?

Sophie D. Fossa, MD

- Challenges and opportunities in developing a cancer survivorship program in the context of current trends in oncology care

Lawrence N. Shulman, MD

- The Needs of Cancer Survivors

Eliezer Robinson, MD

Session Title: #41: Disparities in Cancer Care

Session Type: Education Session

Date: Monday, June 7

Location: S404

Time: 8:00 AM - 9:15 AM

- Complex etiologies and strategies for reducing disparities in cancer care

Beverly Moy, MD, MPH

- Evolving U.S. population demographics and implications for disparities in cancer care

Lisa A. Newman, MD, MPH

- Cancer care in different contexts: Domestic and international perspectives

Michael Silbermann, DMD, PhD

Session Title: #54: Health Disparities in Lung Cancer: Race, Sex, and Genes

Session Type: Education Session

Date: Monday, June 7

Location: E Hall D2

Time: 8:00 AM - 9:15 AM

- Molecular Epidemiology of Lung Cancer: Ancestry Matters
Alex A. Adjei, MD, PhD
- Molecular Genetic Variations Between Human Populations
Patrick C. Ma, MD, MSc
- Impact of Gender on Incidence, Behavior, and Therapy of Lung Cancer

Nithya Ramnath, MD

Session Title: #58: Impact of Health Literacy on Health Care, Decision Making and Consent

Session Type: Education Session

Date: Monday, June 7

Location: E353

Time: 8:00 AM - 9:15 AM

- Impact of limited health literacy; assessing literacy and overcoming barriers to limited literacy in delivering health care
Terry C Davis, PhD
- overcoming literacy issues in obtaining informed consent
Cathy A. Coyne, PhD
- Decision making in breast and prostate cancer

Angela Fagerlin, PhD

Session Title: #156: Health Services Research

Session Type: Oral Abstract Session

Date: Monday, June 7

Location: S404

Time: 9:30 AM - 12:30 PM

- Health Services Research

Sarah T. Hawley, MD, PhD

- #6000-Changes over time in quality of psychosocial care: Results from the Quality Oncology Practice Initiative (QOPI).

Paul B. Jacobsen

- #6001-Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials.

Steven K Cheng

- #6002-Assessment of performance measures for patients with the myelodysplastic syndrome (MDS) in the United States.

Gregory Alan Abel

- Discussion: Implementing performance measures to improve patient care

Steven J. Katz, MD

- #6003-Comparison of SEER registry data to patient self-report.

Reshma Jagsi

- #6004-State-wide application of breast and colon cancer quality measures (QMs) using linked claims and registry data.

Stephen B. Edge, MD

- #6005-Comorbidity severity and long-term mortality in men with early-stage prostate cancer.

Timothy J. Daskivich

- #6006-Development of a performance status prediction model for use in administrative data analyses.

Amy J. Davidoff

- #6007-Adoption of CT-based simulation and outcomes following radiation for stage III non-small cell lung cancer.

Aileen B. Chen

- #6008-Factors influencing the uptake of the human papillomavirus (HPV) vaccine to prevent cervical cancer (CC).

Jennifer YiChun Lai, MD, MPH

- Discussion: Diffusion of therapeutic and preventive innovations

Joseph Lipscomb, PhD

Session Title: #102: Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the NCI's Clinical Trials and Translational Research Advisory Committee

Session Type: Education Session

Date: Monday, June 7

Location: S100a

Time: 9:45 AM - 11:30 AM

- Obstacles to clinical trial development and implementation

David M. Dilts, PhD, MBA

- Streamlining the extramural clinical trials system

James H. Doroshow, MD

- Recommendations by the IOM on Reinvigorating Cooperative Group Clinical Trials

John Mendelsohn, MD

- The Role of Cooperative Groups in Comparative Effectiveness Research

Richard L. Schilsky, MD

Session Title: #7: Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the "New Bad News"

Session Type: Education Session

Date: Monday, June 7

Location: E353

Time: 11:30 AM - 12:45 PM

- Communication about Cost of Cancer Care

Lidia Schapira, MD

- Communicating the Costs and Benefits of Medical Interventions

Deborah Schrag, MD

- Inside the Patient-Physician Encounter: Communication and Value

Anthony Back, MD

Session Title: #204: Health Services Research

Session Type: General Poster Session

Date: Monday, June 7

Location: S Hall A2

18B #6035-RCT of community-based patient assistance to improve breast cancer care.

Nina Bickell

18C #6036-Evaluating psychosocial and belief differences in a diverse racial and socioeconomic cancer population.

Blase N. Polite

18D #6037-Cost-effectiveness of lapatinib plus capecitabine (LAP+C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ+C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the U.K. National Health Service (NHS) perspective.

Oleg Sofrygin

18E #6038-Impact of medicaid-enrollment status/timing on stage at diagnosis among male cancer patients.

Katherine S. Virgo, PhD, MBA

18F #6039-Use of a 21-gene reverse transcriptase-polymerase chain reaction (RT-PCR) assay to guide therapy in 14 Michigan Breast Oncology Quality Initiative (MiBOQI) sites.

Samuel M. Silver, MD, PhD, FACP

18G #6040-Barriers to treatment in patients with locally advanced breast cancer.

Laura Bourdeanu

18H #6041-Physician's perspectives and racial disparity in the surgical treatment of early lung cancer.

Paul R. Walker

19A #6042-Cost-effectiveness of adding information about common risk alleles to current decision models for breast cancer chemoprevention.

Tuan Dinh

19B #6043-Initial use of newer agents for advanced non-small cell lung cancer: Evidence from the National Cancer Institute patterns of care study.

Bernardo Haddock Lobo Goulart

19C #6044-Analysis of the cause of discordance between two radiologists on the assessment of radiographic response and progression for subjects enrolled in breast cancer clinical trials employing blinded independent central review.

Kristin Borradaile, MS

19D #6045-Communication of the essential elements of informed consent (IC) for research: A RIAS analysis of phase I clinical trial encounters.

Christopher Daugherty, MD

19E #6046-The impact of routine pathology review on treatment for node-negative breast cancer.

Hagen F. Kennecke

19F #6047-Characterization of prostate cancer treatment information quality obtained through Yahoo, Google, and Bing search engines.

Danny Landau, MD

19G #6048-Costs of absenteeism and short-term disability associated with breast cancer to U.S. employers.

Sean D Sullivan

19H #6049-Changes in chemotherapy uptake and wait times in early-stage non-small cell lung cancer (NSCLC).

Samantha Lee Gray

20A #6050-Global variations in reimbursement of new cancer therapeutics: Improving access through risk-sharing agreements.

Parneet Kaur Cheema

20B #6051-Medical oncologists and quality of life of women treated for breast cancer.

Christopher Ryan Friese

20C #6052-Equipoise lost: Ethics, costs, and the regulation of cancer clinical research.

David J Stewart

20D #6053-Practice standardization in the staging and treatment of colon cancer at Intermountain Healthcare.

Jonathan R. Whisenant

20E #6054-Impact of cancer on the quality of life and health status of patients and their family members.

Ya-Chen T. Shih

20F #6055-Health care cost of breast cancer: A claims data analysis.

Alex Z Fu

20G #6056-Comparison of the Veterans Affairs Oncology Registry and the SEER Cancer Registry among patients with lung cancer.

Steven B. Zeliadt

20H #6057-Unmet psychosocial needs among cancer patients at the national cancer centre Singapore (NCCS).

Raymond C.H. Ng

21A #6058-Accuracy of cancer information on the Internet: A comparison of a Wiki with a professionally maintained database.

Malolan S Rajagopalan, BS

21B #6059-Quality of published studies supporting off-label and accelerated approval oncology indications.

Kenneth Robert Carson

21C #6060-Effects of ethnicity on genotype-phenotype correlations in individuals with a *BRCA1* or *BRCA2* mutation.

Michelle Jackson, MS, CGC

21D #6061-The impact of breast care nurses on early-stage breast cancer patients' perception of quality of care: The results of a multilevel regression analysis.

Christoph Kowalski

21E #6062-Consenting factors in clinical cancer research: Observations from a cancer center tissue repository.

David E. Gerber

21F #6063-Changing rates of organ-preservation therapy over time for head and neck cancer: A SEER-Medicare analysis.

David J Sher

21G #6064-Social, biological, and tumor characteristics of 139 African American (AA) women with newly diagnosed breast cancer in Chicago.

Sarah J. Gehlert

21H #6065-FDA accelerated approval of anticancer agents.

Yangmin M. Ning

22A #6066-Protocol performance metrics and resource utilization of phase II investigator-initiated trials.

Henry Durivage

22B #6067-Factors influencing use of genetic tests in clinical practice among U.S. oncologists.

Jeffrey M. Peppercorn, MD, MPH

22C #6068-Treatment delays in non-small cell lung cancer (NSCLC) and their prognostic implications.

Razvan Diaconescu, MD

22D #6069-Nature and outcome of clinical trials conducted by the Eastern Cooperative Group (ECOG) from 1977 to 2006.

Ronald S. Go

22E #6070-Factors contributing to delays in breast cancer management.

Erica Barlow

22F #6071-Impact of Medicare's July 2007 erythropoiesis-stimulating agent (ESA) national coverage determination (NCD) on transfusion use in chemotherapy-treated cancer patients.

Tom Arneson

22G #6072-Influence of patient beliefs and patient knowledge on adherence to hormone treatment for breast cancer.

Kathie-Ann P. Joseph

22H #6073-Understanding premature discontinuation of aromatase inhibitor (AI) therapy in postmenopausal breast cancer survivors.

Carrie Tompkins Stricker

23A #6074-Predictors of BRCA-positive parents' disclosure of cancer risk and risk reduction options to offspring.

Linda J. Patrick-Miller

23B #6075-The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel.

Shmuel Klang

23C #6076-Follow-up of abnormal pap smear results: A population-based study.

Rachel Kupets

23D #6077-NCI Cancer Trials Support Unit at year 10.

Stephen E Riordan

23E #6078-Retrospective health care claims database analysis of direct medical costs of newly diagnosed patients (pts) with hepatocellular carcinoma (HCC) in the United States.

Andrew Stewart Poklepovic

23F #6079-Using administrative data to describe adherence to colon cancer follow-up testing in Manitoba, Canada.

Jeffrey J Sisler

23G #6080-Information technology (IT) and chemotherapy (CT) prescribing errors.

Marianna Aita

23H #6081-Strategies to increase access to quality genetic testing services: Case study of BRCA1/2 testing.

Benjamin Kim

24A #6082-Synergy made simple: What does it mean and how valid are claims for synergy between antitumor agents?

Alberto Ocana

24B #6083-Treatment patterns by oncologists and urologists for castration-resistant prostate cancer (CRPC).

Berhanu Alemayehu, DrPH

24C #6084-Analysis of cancer clinical trials in the United States with comparison of National Institute of Health (NIH) and pharmaceutical industry (PHARMA)-sponsored studies.

Kurt R. Oettel

24D #6085-Rural-urban disparity in cancer screening among elder Medicare beneficiaries: Does rurality matter?

Lin Fan

24E #6086-Small world networks and treatment discovery process in cancer.

Athanasios Tsalatsanis

24F #6087-Baseline MUGA scans for patients with early-stage breast cancer receiving adjuvant chemotherapy.

Alwin S. Jeyakumar

24G #6088-Neutropenic risk, use of colony-stimulating factors, and impact on the relative dose intensity of administered chemotherapy.

William Baxter Webb

24H #6089-A prospective evaluation of the patients' knowledge about their chemotherapy treatment (CT) before the first course.

Nelson Kohen

25A #6090-Dose reductions and delays in patients (pts) with renal cell carcinoma (RCC) treated with sorafenib (SR) or sunitinib (SU): Retrospective analysis of two large U.S. health care claims databases.

Stephen Michael Keefe

25B #6091-Pattern of aromatase inhibitor use in males.

Milayna Subar

25F #6092-Concomitant medication (CM) use in phase I and II cancer clinical trials (CCT): Effects on trial eligibility and potential interactions with study medications.

Martin Benjamin

25G #6093-Evaluation of multidisciplinary (MultiD) care in thoracic oncology.

Gregory L Phelps

25H #6094-The role of NCI-sponsored research in ASCO clinical cancer advances 2005-2008.

Brian Zuckerman, PhD

26A #6095-Adherence to cardiovascular (CV) medications after myocardial infarction (MI) in cancer survivors (CS).

Soko Setoguchi

26B #6096-Quality and consistency in breast cancer clinical guidelines internationally: Are we globally consistent?

Christine E. Simmons

26F #6097-The relationship between service quality measures and patient willingness to recommend at a national oncology provider network: The Cancer Treatment Centers of America experience.

Digant G Gupta

26G #6098-Patients' views on delayed diagnosis in cancer.

Thomas H. Gallagher

26H #6099-Optimal chemotherapy utilization rate in cancer care: Setting an evidence-based benchmark for quality improvement.

Weng Leong Ng

27A #6100-Patients' willingness to be informed on cancer clinical trials.

Iris Pauporte

27B #6101-Utility of routine cardiac ejection fraction (EF) measurement prior to anthracycline-based chemotherapy (ABC) in patients with diffuse large b-cell lymphoma (DLBCL).

Amber L Conrad, MS, PA-C

27C #6102-Treatment strategies for low-risk febrile neutropenia in adult cancer patients: A cost-utility analysis.

Oliver Teuffel

27D #6103-What are physician and patient factors important for proper follow-up of high-grade Pap smear abnormalities?

Lawrence Frank Paszat

27E #6104-The shortage of medical oncologists and low chemotherapy utilization in Australia.

Bogda Koczwara

27F #6105-Nomogram to predict risk of 30-day mortality for patients with disseminated malignancy undergoing surgical intervention.

Warren H Tseng

27G #6106-Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network.

Marcus A. Neubauer

27H #6107-Association of black race and outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC): Results from a U.S. local oncology practice.

Bruce A. Feinberg

28A #6108-Calibration of quality-adjusted life years (QALYs) for oncology clinical trials (OCT).

Jeff A. Sloan

28B #6109-Relationship between neuroendocrine tumor-related symptoms and PROMIS health-related quality-of-life scores.

Jennifer L Beaumont

28C #6110-The value of concurrent symptoms in predicting clinical outcomes in lung cancer survivors.

Andrea L. Cheville

28D #6111-Prospective change in 25-OH vitamin D levels over long-term follow-up and health outcomes in breast cancer survivors.

Sara Kristina Taylor, MD, CM

28E #6112-Estimating minimally important differences (MID) for the worst pain rating of the brief pain inventory (BPI)-short form (SF).

Susan D. Mathias

28F #6113-The long-term impact of surgical complications after resection of stage I non-small cell lung cancer: A population-based survival analysis.

Natasha M Rueth

28G #6114-Cancer recurrence and survival in patients with early-stage triple-negative breast cancer in a U.S. local oncology practice.

Lirong Zhao

28H #6115-Evaluation of the state of health of patients with localized prostate cancer (cT1-cT2) compared to the normal population.

Michael J. Mathers, MD, PhD

29A #6116-Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings.

Alessandro I. C. Leal, MD

29B #6117-The role of acculturation in end-of-life outcomes for Latino advanced cancer patients.

Elizabeth Trice Loggers, MD, PhD

29C #6118-Neuroendocrine tumor disease state and PROMIS health-related quality of life scores.

David Cella

30A #6119-Racial disparities in stage II prostate cancer outcomes in the Veterans Affairs hospital system.

David Crockett

30B #6120-A prospective paired survey of oncologist and patient attitudes toward therapeutic cancer clinical trial (CT) enrollment in a diverse academic health center patient population.

Mandira Ray

30C #6121-Impact of response shift in longitudinal postoperative quality of life (QoL) analysis among breast cancer (BC) patients: A randomized multicenter cohort study.

Franck Bonnetain

31A #6122-Adequacy of data provision and analysis in oncology phase III trials over the past 5 years.

Hui Kong Gan

31B #6123-The National Lung Cancer Audit in the United Kingdom: Results after four years.

Paul Beckett

31C #6124-Education level as prognostic factor of patients (pts) with advanced non-small-cell lung cancer (NSCLC) enrolled in clinical trials.

Massimo Di Maio

32A #6125-Relationship between survival and lymph node assessment from a population-based study of colorectal cancer patients.

Robin Urquhart

32B #6126-Comparison between the causes of rejection to participate (RP) and screening failures (SF) in oncology clinical trials (OCT).

Luis A Fein

32C #6127-Outcomes from placebo/best supportive care-controlled trials (PBSCT) in the era of molecular targeted therapy: A meta-analysis.

Michele C. Miranda

33A #6128-Is the informed consent (IC) to treatment truly "informed"? The use of a comprehension check tool (CCT).

Rosalbino Biamonte

33B #6129-Assuring continuous quality improvement using outcomes data: A potential role for cancer registries.

Robert Owen Dillman

33C #6130-Evaluation of hormone receptor and benefit from adjuvant chemotherapy in breast cancer patients with intermediate- and high-risk disease.

Christian Kurzeder

34A #6131-Second-line pancreatic cancer therapy: Patterns of care and survival.

Susan Nga Hoang

34B #6132-Effect of race and comorbidities on patterns of bevacizumab toxicity: A single-institution experience.

Muhammad Raza

34C #6133-Symptom burden in chronic myeloid leukemia (CML).

Loretta A. Williams

35A #6134-Correlation of 5-year survival and cure in NSCLC: An analysis of delayed cancer deaths in long-term survivors of NSCLC.

Matthew O. Hubbard

35B #6135-Impact of neoadjuvant chemotherapy on breast reconstruction.

Yue-Yung Hu

35C #6136-Can patient-reported kidney cancer–specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma?

Peter C Trask

35D #6137-Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting.

J. Russell Hoverman

35E #6138-Capturing breast cancer patients' experience beyond disease progression: Implementation of a patient-reported outcome (PRO) substudy in the VIRGO Metastatic Breast Cancer Observational Cohort study.

Peter Andrew Kaufman

35F #6139-Retrospective application of Nottingham Prognostic Index (NPI) and Adjuvant! Online tool in newly diagnosed patients with early breast cancer in mid-western Ireland.

Keith Ian Quintyne

35G #6140-Cost and outcome of vascular resections during pancreaticoduodenectomy.

Griffin Bullock

35H #6141-Technologic advancements and error rates in radiation therapy (RT) delivery.

Danielle Nina Margalit, MD, MPH

36A #6142-Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service.

David A Hanauer

36B #6143-Novel uses of coded data in clinical trials.

Adam Daunton

36C #6144-Factors influencing the career decisions of United States hematology oncology fellows training at NCI- and NCCN-designated cancer centers.

Leora Horn

36D #6145-Continuity of care for cancer patients at the end of life (EoL).

Romeo Bascioni

36E #6146-Care delivery barriers to personalized medicine in breast cancer.

Julian C. Schink

36F #6147-Hepatitis B screening prior to chemotherapy: A survey of practitioners' knowledge, beliefs, and screening practices.

Ronita Lee

36G #6148-The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB).

Mira L Katz

36H #6149-Prescribing and safety issues of oral molecular therapies and chemotherapies in Australian haematology oncology practice.

Michael Joseph Dooley

37A #6150-Comparison of hospital costs versus DRG reimbursement for treatment of febrile neutropenia during adjuvant CTX for primary breast cancer.

Stefanie C Mayer

37B #6151-Development and testing of multiple versions of a radiation oncology treatment planning workflow application in the era of HIPAA.

John B. Fiveash

37C #6152-Evaluating clinical trials: What exactly do medical oncologists know and use?

Kenneth Robert Hoffman, MD, MPH

37D #6153-Quantitative aspects of failure mode and effects analysis (FMEA) scoring in a prospective safety study of a large academic radiation oncology department.

Stephanie Alicia Terezakis

37E #6154-The 2008 National Comprehensive Cancer Network (NCCN) research benchmarking survey (RBS): Clinical trials (CTs) operations in the academic center.

Stephen L Sherman

37F #6155-Toxicity symptom reporting by patients and clinicians during phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer (GETUG-AFU 15/0403).

Gwenaëlle Gravis

37G #6156-ERCC, TS, RRM1, EGFR, and KRAS biomarker integration into a community-based medical oncology practice.

Sandeep K. Reddy

37H #6157-Fellowship characteristics associated with fellows' interest in pursuing clinical research: A National Comprehensive Cancer Network (NCCN) survey.

Jennifer M Hinkel

38A #6158-Physicians' nonverbal behaviors: Oncology patients perspective.

Harris V. K. Naina

Session Title: #22: Caring for the Child with Brain Cancer

Session Type: Education Session

Date: Monday, June 7

Location: S504

Time: 3:00 PM - 4:15 PM

- High Dose Chemotherapy for Malignant Brain Tumors- What have we learned in the past 2 decades and what does the future hold for this therapy

Amar J. Gajjar, MD

- Relapsed Pediatric CNS tumors in 2010 □strategies and new agents

Stewart Goldman, MD

- Understanding Late Effects of Irradiation and Measures to Reduce Dose to Normal Tissue

Thomas E. Merchant, DO, PhD

Session Title: #85: Oral Chemotherapy: A Hard Pill to Swallow

Session Type: Education Session

Date: Monday, June 7

Location: S406 (Vista Room)

Time: 4:45 PM - 6:00 PM

- General issues relevant to oral chemotherapy and patient health care literacy

- Drug-drug and food-drug interactions relevant to oral chemotherapy agents

Jan Hendrik Beumer, PhD, PharmD

- Adherence and persistence (or lack thereof) with oral agents. The scope of the problem. What the data say.

Ann H. Partridge, MD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III

Kathy Miller, MD

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy

Kathy Miller, MD

- Discussion: Lung Cancer - Metastatic

Charles M. Rudin, MD, PhD

- Discussion: Sarcoma

Gary K. Schwartz, MD

- Discussion: Gastrointestinal (Noncolorectal) Cancer

C. D. Blanke, MD

- Discussion: Head and Neck Cancer

Everett E. Vokes, MD

Session Title: #27: Comparative Effectiveness Research in Oncology: Opportunities and Challenges

Session Type: Education Session

Date: Tuesday, June 8

Location: S404

Time: 8:00 AM - 9:15 AM

- Comparative effectiveness research: what is it and why is it important?

Gary H. Lyman, MD, MPH

- Comparative effectiveness research to address uncertainties in oncology practice

Neal J. Meropol, MD

- Methods of comparative effectiveness research in oncology

Jerome Seidenfeld, PhD

Session Title: #90: Localized Prostate Cancer: Reducing Mortality and Burden of Therapy

Session Type: Education Session

Date: Tuesday, June 8

Location: E Arie Crown Theater

Time: 8:00 AM - 9:15 AM

- Everything you need to know about prostate cancer screening

Andrew J. Stephenson, MD

- Elevated PSA: Biopsy or Chemoprevention?

David C Miller, MD

- What is "active surveillance" and what is its role in management today?

Laurence Klotz, MD, FRCSC

Session Title: #25: Closing the Loop: Evidence, Guidelines, Reporting, and Quality

Session Type: Education Session

Date: Tuesday, June 8

Location: S100a

Time: 9:30 AM - 10:45 AM

- Quality reporting, measurement and feedback

Craig Earle, MD

- Barriers to quality improvement initiatives

Sandra L. Wong, MD, MS

- Distilling research and evidence into opportunities for quality improvement

Gary H. Lyman, MD, MPH

Session Title: #69: Management of the Elderly Patient with Cancer**Session Type:** Education Session**Date:** Tuesday, June 8**Location:** S100b**Time:** 11:30 AM - 12:45 PM

- Under representation of the elderly in clinical trials and implications for comparative effectiveness research

Cary P. Gross, MD

- Assessing the elderly for therapy

Arti Hurria, MD

- Generalizability of clinical trials to the elderly

Elizabeth B. Lamont, MD, MS